Literature DB >> 12947364

Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction.

Shinzo Miyamoto1, Tomohiro Sakamoto, Hirofumi Soejima, Hideki Shimomura, Ichiro Kajiwara, Sunao Kojima, Jun Hokamaki, Seigo Sugiyama, Michihiro Yoshimura, Yukio Ozaki, Hajime Nakamura, Junji Yodoi, Hisao Ogawa.   

Abstract

BACKGROUND: Oxidative stress is thought to play an important role in atherosclerotic vascular disease. Recently, it has become possible to quantitatively measure thioredoxin, a marker of oxidative stress in human plasma. A platelet aggregometer that uses laser-light scattering enables minimal changes in platelet aggregability to be monitored; however, the relationship between oxidative stress and platelet aggregability in vivo is not well understood.
METHODS: We investigated plasma thioredoxin levels and platelet aggregability, in particular small platelet aggregates, in 45 patients with acute myocardial infarction (AMI); we compared the results with 33 patients with stable exertional angina (SEA) and 30 patients with chest pain syndrome (CPS).
RESULTS: The plasma thioredoxin levels and the degree of small platelet aggregates were higher in the AMI group than in the SEA and the CPS groups: in the AMI group, at 4 weeks after admission, both of those parameters were significantly decreased (P <.01), but they were still higher (P <.05) than in the SEA or the CPS group. There was a significant positive correlation between small platelet aggregates and plasma thioredoxin levels (rho = 0.354, P =.0002). We divided the AMI patients into 2 groups according to the 75 percentile of plasma thioredoxin levels on admission. At the chronic phase, the left ventricular ejection fraction was significantly higher in the lower thioredoxin group than in the higher thioredoxin group.
CONCLUSIONS: We showed that plasma thioredoxin levels and platelet aggregability increased concomitantly in patients with AMI. In these patients, increased plasma thioredoxin was associated with platelet hyperaggregability and lower left ventricular ejection fraction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947364     DOI: 10.1016/S0002-8703(03)00311-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Constitutively oxidized CXXC motifs within the CD3 heterodimeric ectodomains of the T cell receptor complex enforce the conformation of juxtaposed segments.

Authors:  Kristine N Brazin; Robert J Mallis; Chen Li; Derin B Keskin; Haribabu Arthanari; Yuanwei Gao; Shiaw-Lin Wu; Barry L Karger; Gerhard Wagner; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2014-05-21       Impact factor: 5.157

Review 2.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

3.  Changes in thioredoxin concentrations: an observation in an ultra-marathon race.

Authors:  Mitsuhiro Marumoto; Sadao Suzuki; Akihiro Hosono; Kazuyuki Arakawa; Kiyoshi Shibata; Mizuho Fuku; Chiho Goto; Yuko Tokudome; Hideki Hoshino; Nahomi Imaeda; Masaaki Kobayashi; Junji Yodoi; Shinkan Tokudome
Journal:  Environ Health Prev Med       Date:  2009-12-04       Impact factor: 3.674

Review 4.  Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart.

Authors:  Md Kaimul Ahsan; Istvan Lekli; Diptarka Ray; Junji Yodoi; Dipak K Das
Journal:  Antioxid Redox Signal       Date:  2009-11       Impact factor: 8.401

Review 5.  Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets.

Authors:  Jose Luis Martin-Ventura; Raquel Rodrigues-Diez; Diego Martinez-Lopez; Mercedes Salaices; Luis Miguel Blanco-Colio; Ana M Briones
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

Review 6.  Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target.

Authors:  Khadija El Hadri; Rémy Smith; Eric Duplus; Chahrazade El Amri
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

Review 7.  Cell stress proteins in atherothrombosis.

Authors:  Julio Madrigal-Matute; Roxana Martinez-Pinna; Carlos Ernesto Fernandez-Garcia; Priscila Ramos-Mozo; Elena Burillo; Jesus Egido; Luis Miguel Blanco-Colio; Jose Luis Martin-Ventura
Journal:  Oxid Med Cell Longev       Date:  2012-06-25       Impact factor: 6.543

Review 8.  Anti-Inflammatory Thioredoxin Family Proteins for Medicare, Healthcare and Aging Care.

Authors:  Junji Yodoi; Yoshiyuki Matsuo; Hai Tian; Hiroshi Masutani; Takashi Inamoto
Journal:  Nutrients       Date:  2017-09-29       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.